Skip to main content

Table 3 Effect of using 3 different corticosteroids on clinical and biochemical outcomes of the treatment groups (represented as (mean ± SD))

From: The effectiveness and pharmacoeconomic study of using different corticosteroids in the treatment of hypersensitivity pneumonitis

Parameter

Betamethasone (N = 35)

Dexamethasone (N = 33)

Prednisolone

(N = 39)

P-Value*

(across groups)

P-Value*

(within the same group)

FEV1(% predicted)

58.34 ± 22.46

56.38 ± 16.1

59.59 ± 21.21

0.797Θ

B: 0.264â—Š

D: 0.082â—Š

P: 0.308â—Š

FVC (% predicted)

64.97 ± 18.54

63.59 ± 14.96

63.57 ± 19.46

0.932Θ

B: <0.001â—Š

D: <0.001â—Š

P: 0.016â—Š

FEV1/FVC Ratio

85.37 ± 12.59

85.09 ± 10.42

82.41 ± 12.78

0.506Θ

B: 0.347â—Š

D: 0.965â—Š

P: 0.7â—Š

6MWD (m)

273.3 ± 69.9

268.94 ± 71.74

256.45 ± 103.15

0.672Θ

B: 0.001â—Š

D: 0.002â—Š

P: 0.002â—Š

Desaturation (% SpO2)

6.37 ± 5.61

5.48 ± 4.5

7.71 ± 6.64

0.256Θ

B: 0.001â—Š

D: 0.001â—Š

P: 0.05â—Š

KL-6 (U/ml)

554.48 ± 129.69

578.7 ± 91.92

671.88 ± 162.63

0.001ΘΔ

B: <0.001â—Š

D: 0.054â—Š

P: 0.921â—Š

ESR (mm)

38.77 ± 21.13

30.06 ± 16.04

42.3 ± 24.52

0.048ΘΔ

B: <0.001â—Š

D: <0.001â—Š

P: <0.001â—Š

CRP (mg/L)

12.29 ± 13.33

9.1 ± 4.79

15.34 ± 15.36

0.105Θ

B: 0.003â—Š

D: <0.001â—Š

P: 0.006â—Š

  1. FEV1: forced expiratory volume after 1 s; 6MWD: six-minute walk distance
  2. FVC: forced vital capacity; SpO2: peripheral capillary oxygen saturation
  3. B: betamethasone group; D: dexamethasone group
  4. P: prednisolone group; â—Š Paired T-test
  5. * Level of Significance at p < 0.05; Θ One way ANOVA test
  6. Δ Adjustment for multiple comparisons: Bonferroni